Company Overview and News


Add REGN
to your dashboard

Headline News

Regeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group Rank

2017-11-21 investorplace
Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. With proprietary fundamental and quantitative analytical tools developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 5 months. (12-0)

Cramer Remix: My query for GE is 'Did you mislead us or yourselves?'

2017-11-14 cnbc
CNBC's Jim Cramer was looking for some reassurance when he and his "Squawk on the Street" colleagues Carl Quintanilla and David Faber interviewed the CEO of General Electric on Tuesday. (33-1)

Weak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating

2017-11-13 investorplace
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health Care sector. REGN has a market value of $43.4 billion which is in the top 10% of its industry group. The ranking for REGN by Portfolio Grader places it 173 among the 349 companies in this industry group, giving it an above-average position; in the third quartile of the sector with a ranking of 404 among the 782 companies in the sector, and number 2,615 in the nearly 5,000 company Portfolio Grader universe. (12-0)

The Week That Was In Review - November 10, 2017

2017-11-13 seekingalpha
A closer look at competing tax proposals from the House and Senate portends a lot more work yet to be done – here come the lobbyists! (149-1)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

2017-11-09 zacks
Ophthotech Corporation (OPHT - Free Report) reported earnings of $5.25 per share for the third quarter of 2017, beating the Zacks Consensus Estimate of $4.38. The company had reported a loss of $1.71 in the year-ago quarter. (38-1)

Regeneron's Long-Term Issues Linger - Bloomberg Gadfly

2017-11-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (114-0)

Regeneron Pharmaceuticals (REGN) Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Welcome to the Regeneron Pharmaceuticals Q3 2017 earnings conference call. My name is Paulette, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded. (13-0)

Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

2017-11-08 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) reported third-quarter of 2017 results wherein both earnings and sales beat expectations on the back of strong performance of eye-care drug Eylea. (45-0)

Regeneron (REGN) Q3 Earnings Beat Estimates

2017-11-08 zacks
Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent. (30-0)

Stock futures slightly lower as investors track progress on tax bill

2017-11-08 reuters
(Reuters) - U.S. stock index futures were slightly lower on Wednesday, a day after the Dow closed at a record high for the fourth straight day, as investors closely watch Republican efforts to pass the tax bill. (13-0)

Regeneron's stock rallies after profit and sales rise above expectations - MarketWatch

2017-11-08 marketwatch
Shares of Regeneron Pharmaceuticals Inc. REGN, -0.55% rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased to $388.3 million, or $3.32 a share, from $264.8 million, or $2.27 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $3.99, beating the FactSet consensus of $3. (12-0)

Stock futures slightly lower as investors track progress on tax bill - Channel NewsAsia

2017-11-08 channelnewsasia
U.S. stock index futures were slightly lower on Wednesday, a day after the Dow closed at a record high for the fourth straight day, as investors closely watch Republican efforts to pass the tax bill. (13-0)

BRIEF-Regeneron Q3 non-GAAP earnings per share $3.99

2017-11-08 reuters
* Regeneron Pharmaceuticals Inc - qtrly EYLEA U.S. net product sales $‍953​ million versus $854 million (12-0)

CUSIP: 75886F957